Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline cancer risk alleles drive myelodysplastic neoplasms throughout adulthood.

Leukemia·2026
Same author

Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder.

Blood advances·2026
Same author

Focusing a sPOTlight on POT1.

Blood·2026
Same author

Update of germ line RUNX1 variant curation rules: version 3.1.

Blood advances·2026
Same author

Correspondence on "ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Lee et al.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.

Leukemia·2026

Related Experiment Video

Updated: Nov 28, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Identifying potential germline variants from sequencing hematopoietic malignancies.

Ira L Kraft1, Lucy A Godley1,2

  • 1Section of Hematology/Oncology, Department of Medicine and The University of Chicago Comprehensive Cancer Center and.

Blood
|November 25, 2020
PubMed
Summary

Next-generation sequencing (NGS) helps identify genetic variants in blood cancers. This study details a method to distinguish between germline and somatic variants, crucial for patient care and risk assessment.

More Related Videos

Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.6K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.0K

Related Experiment Videos

Last Updated: Nov 28, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.6K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.0K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Next-generation sequencing (NGS) is vital for diagnosing and monitoring hematological malignancies.
  • Distinguishing germline from somatic DNA alterations in tumor samples is clinically challenging.

Observation:

  • A novel approach is presented to identify potential germline variants using patient history, variant characteristics, and sequential NGS assays.
  • Criteria for identifying individuals with deleterious germline variants include family cancer history, early-onset malignancy, high variant allele frequency in predisposition genes, and variant persistence.
  • Sequential molecular testing of hematopoietic specimens offers insights into disease pathology.

Findings:

  • The described approach effectively utilizes clinical data and sequential NGS to differentiate germline variants from somatic mutations.
  • Established criteria aid in identifying patients with a higher likelihood of harboring germline predisposition variants.
  • Persistent variants across different disease states suggest a germline origin.

Implications:

  • Identifying germline variants can significantly impact patient and family member care, including genetic counseling and risk assessment.
  • This approach may lead to the discovery of novel cancer-predisposing risk alleles.
  • Obtaining patient consent for germline variant information and future research contact is essential for advancing personalized medicine.